Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome. JOC [Internet]. 2025 Sep. 12 [cited 2025 Dec. 6];24(3s):441-8. Available from: https://carcinogenesis.com/index.php/JOC/article/view/761